Publications

Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals.

Neuen BL. et al, (2026), Nat Med

Recommendations for Pre-Analytical Urine Sample Handling To Allow Optimal Assessment of Albuminuria and Proteinuria A consensus report of the USA NKF Albuminuria - Proteinuria Workshop.

Ridderbos S. et al, (2026), Nephrol Dial Transplant

Association of UACR and UPCR with kidney failure: a pooled analysis of clinical trials.

Mepschen M. et al, (2026), Nephrol Dial Transplant

Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY.

Malijan GB. et al, (2026), Am J Kidney Dis, 87, 553 - 563.e1

Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic Substudy.

Zhu D. et al, (2026), Am J Kidney Dis, 87, 564 - 568

Metabolomic Profile of Genetic Liability to Type 2 Diabetes Among 125,000 Mexican Adults: A Mendelian Randomization Study.

Bragg F. et al, (2026), Diabetes Care

Polygenic prediction of coronary heart disease among 130 000 Mexican adults.

Liu T. et al, (2026), Eur J Prev Cardiol, 33, 415 - 423

Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.

Cholesterol Treatment Trialists' (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk . and Cholesterol Treatment Trialists' (CTT) Collaboration ., (2026), Lancet, 407, 689 - 703

Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria: A Meta-Analysis.

Staplin N. et al, (2026), JAMA, 335, 220 - 232

SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis.

Neuen BL. et al, (2026), JAMA, 335, 233 - 244

Chronic Kidney Disease: Implications for Cardiovascular Risk and Management in Patients With Type 2 Diabetes

Herrington WG. and Haynes R., (2026), 353 - 368

Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis.

Herrington WG. et al, (2025), Lancet Diabetes Endocrinol, 13, 1003 - 1014

An application of the MR-Horse method to reduce selection bias in genome-wide association studies of disease progression.

Donovan K. et al, (2025), Eur J Hum Genet, 33, 1677 - 1683

"Hi"s and "Lo"s of Targeting Serum Phosphate Levels in Hemodialysis.

Mayne KJ. and Herrington WG., (2025), J Am Soc Nephrol, 36, 2328 - 2329

In CKD, electronic letter nudges for patients or providers did not increase RASi or SGLT2i prescriptions at 6 mo.

Turnbull I. et al, (2025), Ann Intern Med, 178

Search results (208)